Involvement of Bone in Systemic Endocrine Regulation. Review

IVANA ZOFKOVA

Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic

Endocrine Functions of Bone

Corresponding author: Prof. Ivana Zofkova, MD, DSc

Institute of Endocrinology, Narodni 8, 11694 Prague 1, Czech Republic

E-mail: izofkova@endo.cz; izofkova@upcmail.cz
Summary

The skeleton shows an unconventional role in the physiology and pathophysiology of the human organism, not only as the target tissue for a number of systemic hormones, but also as endocrine tissue modulating some skeletal and extraskeletal systems. From this point of view, the principal cells in the skeleton are osteocytes. These cells primarily work as mechano-sensors and modulate bone remodelling. Mechanically unloaded osteocytes synthetize sclerostin, the strong inhibitor of bone formation and RANKL, the strong activator of bone resorption. Osteocytes also express hormonally active vitamin D (1,25(OH)\(_2\) D) and phosphatonins, such as FGF23. Both 1,25(OH)\(_2\) D and FGF23 have been identified as powerful regulators of the phosphate metabolism, including in chronic kidney disease. Further endocrine cells of the skeleton involved in bone remodelling are osteoblasts. While FGF23 targets the kidney and parathyroid glands to control metabolism of vitamin D and phosphates, osteoblasts express osteocalcin, which through GPRC6A receptors modulates beta cells of the pancreatic islets, muscle, adipose tissue, brain and testes. This article reviews some knowledge concerning the interaction between the bone hormonal network and phosphate or energy homeostasis and/or male reproduction.

Introduction

Bone is traditionally understood not only as a mechanical frame, but also as the tissue targeting a number of hormones, such as 1,25(OH)₂ vitamin D, calcitonin, sexual steroids, glucocorticoids and thyroid hormones (Dumic-Cule I, et al. 2014). Recently, the skeleton has been shown to be an endocrine organ producing molecules, which via autocrine/paracrine level modulate bone homeostasis, but significantly also some extra-skeletal systems.

Bone remodelling is derived from the close interaction between osteoblasts (cells of mesenchymal origin) stimulating bone formation and osteoclasts (cells of monocyte-macrophage lineage) activating bone resorption. A number of osteoblastic cytokines interfere with RANK and in this way inhibit osteoclastogenesis and bone resorption, respectively (reviewed by Kitamura et al., 2013). Maturation of osteoblasts is promoted by the canonical Wnt (wingless proteins) pathway, as well as by the hormones synthesized in the osteocytes, such as 1,25(OH)₂ D₃ (Turner et al., 2014) and/or growth factors, e.g. BMP-4 (activated by the p38 MAP kinase) (Kondo et al., 2014). Autoregulation processes, such as acceleration of osteoclastic apoptosis together with the activation of osteoblastic differentiation, start when bone resorption is activated in a way that it prevails over the bone formation. At this moment, the metabolic equilibrium of the healthy skeleton resets to the physiological level (Nakahama, 2010).

The role of osteocytes in bone homeostasis

In the adult skeleton, osteocytes are without doubt the most abundant multifunctional cells of the bone matrix, interconnecting with each other and with other cells, such as osteoblast, lining cells and stromal cells via the cell network. Osteocytes are long-lived cells, which occupy the lacunae, contained in calcified matrix of the skeleton. They are involved in bone remodelling transmitting signals to other osteocytes in response to deformation of bone. These
cells are derived from osteoblasts and ocupies small channels cannaliculi. Osteocytes are fundamental sensors of mechanical loading, which trigger anabolic mechanisms in the skeleton. The cells are activated depending on the intensity and the duration of the strain. The mechanical impulse is transmitted through the canalicular system into the cytoplasm and after humoral signalizations through the second messengers, such as nitric oxide, prostaglandin E and/or Wnt/β-catenin signalling positively modulates bone formation (Turner et al., 2009; Delgado-Calle and Bellido, 2015; Neve et al., 2012; Dallas et al., 2013;; Capulli et al., 2014; Spatz et al., 2015; Nakahama, 2010; Sapir-Koren and Livshits, 2014). Repp et al. (2017) observed decrease in canalicular density and quantity within osteons of the aging human skeleton due to micropetrosis. The authors outlined the hypothesis, that this phenomenon inhibits the mechano-sensitivity of the skeleton in elderly subjects. Mechanically unloaded osteocytes synthetize sclerostin, the strong inhibitor of bone formation and RANKL, the strong activator of bone resorption. Sclerostin is antagonist of Wnt/betacatenin pathway, working as a negative local/paracrine regulator of bone formation. An interesting preliminary report from an experimental study on porcine explants (which is prepared to be published in Bone by Curtis et al., 2017) suggests that mechanical stimulation and a subsequent increase in trabecular bone formation could also be transduced in bone marrow, independently from osteocyte signalling. Therefore, the influence of mechanical stress on bone metabolism appears to be more complex.

The favourable effect of mechanical loading on the skeleton and the detrimental influence of unloading are documented by a number of experimental and clinical studies.

Sclerostin plays a crucial role in the regulation of the mechano - sensitivity of the skeleton. The molecule is expressed by osteocytes. Experimental studies have shown, that mechanical unloading of osteocytic cell line (Ocy454) stimulates sclerostin production and, via an increase in RANKL/OPG ratio activates bone resorption (Spatz et al., 2015).
Furthermore, sclerostin is the osteocytic antagonist of Wnt/\(\beta\)-catenin pathway, working as a negative local/paracrine regulator of bone formation (Drake and Khosla, 2017). Sclerostin deficiency in humans and animals could be induced by long-term treatment with sclerostin antibodies (Appelman-Dijkstra and Papapoulos 2016; McClung, 2017).

A gradual physiological increase in circulating sclerostin has been observed in the course of the menopausal transition to early postmenopause, which is associated with the relative decrease in bone formation compared to actual bone resorption (Matsui et al., 2016). In this respect, sclerostin appears to be an effective marker for monitoring the dynamics of bone homeostasis during the early menopause. Kalem et al. (2017) and some others (Mödder et al., 2011) reported a negative association between blood sclerostin levels and BMD in postmenopausal women. Studies in humans and animals have demonstrated the suppressive effects of estrogen on circulating sclerostin (reviewed by Drake and Khosla, 2017). Thus, estrogen appears to be an effective physiological inhibitor of sclerostin and supports the role of high sclerostin levels in the development of postmenopausal osteoporosis.

Alarming data were obtained from healthy male athletes, where higher sclerostin levels were found after long-term physical training, not related to other bone turnover markers and PTH (Zagrodna et al., 2016). Moreover, higher sclerostin levels were also observed in subjects with prediabetes, where sclerostin levels correlated with insulin sensitivity. On the other hand, carboxylated osteocalcin correlated with insulin resistance in obese postmenopausal women. Nevertheless, recently was observed, that osteocalcin signalling in myofibers is needed for optimal adaptation to exercise (Mera P, 2016).

In uremic patients with low metabolic turnover, an exaggerated expression of sclerostin is found. Sclerostin levels in circulation increased in the pre-hemodialysis period and declined
in post hemodialysis. Sclerostin correlated with parameters of dialysis adequacy, such a creatinine levels and could represent a defensive mechanism, leading to improvement of vascular disease and bone homeostasis (Bruzzese et al., 2016). From this point of view, sclerostin antagonists possess a potential role in the treatment of renal osteodystrophy.

Further molecules expressed by osteocytes are phosphatons, such as FGF23, sFRP-4 and MEPE, which have been mostly identified as powerful regulators of phosphate metabolism (Cavalli et al., 2012; Chapurlat and Confavreux, 2016; Mace et al., 2017). The well recognized phosphatonin FGF23 (fibroblast growth factor 23) is a powerful phosphaturic hormone, which reduces renal transport of phosphates.

The expression of FGF23 is under the control of phosphate, sclerostin and 1,25(OH)₂D (Cavalli et al., 2012; Sapir-Koren, Livshits, 2014) and PTH (Rhee et al., 2011). While ablation of PTH1R reduced serum FGF23 protein levels by 50%, intermitent hPTH(1-34) injection markedly increased Fgf23 mRNA and serum intact FGF23 levels (Fan et al., 2016).

Inactive molecule of vitamin D (25OHD) synthesized in the liver, represents a precursor for dihydroxylated metabolites, including biologically active 1,25(OH)₂ D₃ targetting the intestine, bone and other tissues. The kidney is generally considered to be the major site of synthesis of 1,25(OH)₂ D₃, although this metabolite can also be expressed in extrarenal tissues. There is a feedback between FGF23 gene transcription and vitamin D. While 1,25(OH)₂D₃ positively modulates FGF23 synthesis (Cavalli et al., 2012), FGF23 inhibits 1α-hydroxylase and activate 24-hydroxylase, both of which lead to decrease in circulating 1,25(OH)₂D with subsequent inhibition of bone formation and bone mineralization (Sapir-Koren and Livshits, 2014; Rolvien al., 2017). Moreover, osteocytes, similarly to the the soft tissues (of the intestine and kidney) express specific enzyme transforming the inactive precursor 25(OH)D to 1,25(OH)₂D₃, which targets osteoblasts at the paracrine level and promotes bone formation (Rolvien al., 2017).
The elementary co-receptor of FGF23 is transemembrane protein Klotho (251 aminoacids). It is expressed in the parathyroid glands, kidneys and in low amount in osteoblasts and/or osteocytes. It enables interaction between FGF23 and its receptors. Klotho alpha alone has been identified as an effective anti-aging factor, the synthesis of which declines with age (Kurosu and Kuro-O, 2009). A Klotho-deficient status is associated with premature aging, which is manifested by endothelial dysfunction and accelerated calcinosis of vessels. (Kuro et al., 2017; Vervloet et al., 2014; Olauson et al 2014).

Apart from the bone, parathyroid gland, cardiovascular and central nervous systems, major functions of FGF23 - Klotho system have been discovered in relation to the kidney function. High activity of the FGF23 - Klotho complex signalizes renal injury together with the risk of vascular disease. In mice with renal failure FGF23 treated bone required Klotho to increase FGF23 mRNA (Kaludrejovic et al., 2017). Thus, the anti-aging factor Klotho is crucial for FGF23 production in renal failure.

Increased FGF23 levels are measured during the chronic kidney disease (CKD), when they correlate independently with bone markers (ALP and N-terminal telopeptide levels) and with vertebral fracture occurrence (Quarles, 2012; Kanda et al, 2012). Serum FGF23 fluctuates in relation to renal function and serum PTH and offers diagnostic utiliation in CKD (Rhee et al., 2011; Fan et al., 2016). In the early stage of CKD, FGF23 inhibits renal tubular phosphate reabsorption and reduces serum 1,25(OH)₂D₃ via activation of Cyp24 (Quarles, 2012). Thus, at this moment, the FGF23 - Klotho system works as an adaptive mechanism, which protects the organism against the retention of phosphate and brakes overproduction of PTH, a vascular toxin, which accelerates arterial stiffness and coronary calcification in these patients. During the progression of renal disease, FGF23 continuously increases due to a decrease in renal excretion (reviewed by Mace et al., 2017). In the advanced stages of CKD, an extensive increase in PTH level further stimulates synthesis of FGF23, which otherwise partly
compensates for phosphate retention, but simultaneously induces cardiovascular complications. Overall, serum FGF23 is an effective protective factor against toxic phosphate retention and promising putative marker of cardiovascular risk in the early phase of CKD. Later in CKD, FGF23 expression progressively amplifies (while Klotho declines). Subsequent hyperphosphatemia further accelerates vascular calcification and the risk of cardiovascular mortality in the late phase of CKD markedly increases. Anticalcific ability could be in part restored by the activation of the vitamin D receptor (Quarles, 2012).

In addition to systemic circulation, FGF23 is present in the cerebrovascular fluid. In the course of CKD, the FGF23 is taken up in the hippocampus, where it alters the neuronal morphology and causes memory insufficiency (Hensel et al., 2016). Interestingly, FGF23 and Klothoα have also been found increased in cirrhotic alcoholics. Quintero-Platt et al. (2017) hypothesize that FGF23-Klotho system have some pathophysiological role in cardiovascular disease complicating hypertension, diabetes, left ventricular hypertrophy and obesity.

Mutations in FGF23 and/or Klotho genes lead to hypervitaminosis D, hyperphosphatemia, hyperostosis and ectopic calcifications. Similarly, disruption of the FGF23 – Klotho axis increases phosphate retention and the syndrome of mammal aging (Kuro, 2016). On the other hand, extremely high activity of FGF23 manifests as hereditary or acquired hypophosphatemic rickets (Cavalli et al, 2012; Quarles, 2012).

Finally, FGF23 is an endocrine factor regulating a broad spectrum of systems (Erben, 2016; reviewed by Zofkova, 2015). After modulation by Klotho, a key role of FGF23 is the regulation of phosphate metabolism in patients with damaged kidneys.

**Osteoblasts**
Osteoblasts are cells of mesenchymal origin stimulating bone formation in the process of bone remodelling. The key role here is played by the Wnt-β-catenin pathway, which is antagonized by sclerostin at the local/paracrine level (Drake and Khosla, 2017). Besides the Wnt-β-catenin molecule, osteoblasts carry out osteocalcin (reviewed by Chapurlat and Confavreux, 2016; Cappariello et al., 2016). Expression of the later peptide is under the negative control of the Esp gene, however its bioactivity is also modulated by insulin, leptin, glucocorticoids and the sympathetic nervous system. Osteocalcin is gamma-carboxylated to three glutamic residues, requiring vitamin K reduction by VKORC1 reductase (Ferron et al., 2015). In addition to bone formation, osteocalcin appears to play some role in bone matrix mineralization (partly mediated by IGF signaling) (Zhang et al., 2002). However, recent studies show a broader spectrum of osteocalcin activities working through the specific G-protein coupled receptors GPRC6A. Undercarboxylated (un-osteocalcin) is hormonally active molecule, modulating metabolism of phosphates, 1,25(OH)_{2}D vitamin and some extraskeletal systems, such as male reproduction, cognition and primarily the glucose metabolism (Cappariello et al., 2016). Therefore, ablation of GPRC6A (-/-) induces a scale of metabolic dysregulations (Zoch et al., 2016).

Thus, osteocalcin is a novel hormone, which via GPRC6A receptors controls metabolism of phosphate and 1,25 (OH)\_{2} vitamin D, but also insulin secretion by pancreatic β-cells and fatty acid metabolism in the liver (Pi and Quarles, 2013). Osteocalcin deficient mice showed hyperglycaemia, which was normalized after osteocalcin supplementation (Zoch et al., 2016; Mizokami et al., 2014; Mizokami et al. 2017). In accordance with the experimental data, negative correlations between serum un-osteocalcin and glycaemia, haemoglobin A1c (HbA1c) levels and the parameters of insulin resistance in peripheral tissues, including the muscles (where GPRC6A receptors are also present) have been found in normal women (Weiler et al., 2013). Muscle contraction is characterized by increased insulin sensitivity and in
this tissue. Thus, it could be postulated, that increased GPRC6A expression in muscles during the physical training is the causal mechanism of increased insulin sensitivity in athletes (Levinger et al., 2016). Osteocalcin with its receptors represents a functional coupling between bone and energy metabolism. A negative association between un-carboxylated osteocalcin levels and adiposity has been observed in school children, which allows un-osteocalcin to predict the risk for adiposity in children (Boucher-Berry et al., 2012). Together, osteoblasts are understood as highly specialized endocrine cells targeting energy metabolism at different molecular levels (Anderson et al., 2012; Cappariello et al., 2016; Sato and Takeda, 2016). The complexity of interaction between bone and energy metabolism also documents the fact, that adipocyte-derived leptin inhibits (via the central sympathetic nervous system) osteoblast activity and osteocalcin synthesis and slows down bone formation (Ferron and Lacombe, 2014).

An interesting article published by Simon et al., 2017 reports new data about galectin-3. This molecule is a member of the β-galactoside-binding lectin family expressed in bone, which influences the interplay between osteoblasts-osteoclasts and the renewal of trabecular bone independently of the RANKL/OPG system.

**Bone and male reproduction**

Until now, the relationship between the skeleton and reproduction has been considered to be limited to the regulation of bone remodelling by sexual steroids. It is well known, that androgens and oestrogens are responsible for sexual dimorphism in the development of peak bone mass and the adaptation of bone to mechanical loading. Androgen insufficiency due to an imbalance in the hypophyseal-gonadal axis and/or low activity of enzymes regulating sex steroid production together with disorders in thyroid function, oxidative stress, autoimmunity
and lifestyle, including zinc deficiency in the diet and genetic factors may lead to male infertility (Kumar et al., 2014; Stouffs et al., 2014).

Recently, male reproduction has also been shown to be under the control of the skeleton. Studies in osteocalcin−/− or GPRC6A−/− mice support the stimulating role of osteocalcin through GPRC6A receptors in regulation of circularing LH. Furthermore, steroidogenic enzymes cytochromes P450scC and P450c17 required for synthesis and release of testosterone could be activated by osteocalcin through the GPRC6A receptor localized on Leydig cells (Karsenty and Oury 2014; Oury et al. 2013). However, there is no evidence that the LH-testosterone system modulates osteocalcin expression (Oury et al. 2013; reviewed by Karsenty and Oury, 2014). Thus the interaction between osteocalcin and hormones of reproduction does not allow feedback regulation.

Finally, male fertility appears to be controlled by dual mechanisms, one of which (via osteocalcin) is independent of the hypothalano-pituitary axis. Osteocalcin deficiency could be hypothetically considered to be a new pathogenetic factor responsible for primary testicular failure in men. On the other hand, El-Kamsoushi et al. (2016) did not find any correlation between serum un-osteocalcin, sperm concentration, morphology and motility or between un-osteocalcin and serum testosterone or LH levels. Therefore, the hypothesis that serum osteocalcin has any predictive value in male reproduction remains to be further investigated.

Here it is appropriate to mention the role, which another hormone involved in bone remodelling, 1,25(OH)2 vitamin D, plays in male reproduction. Its receptors, as well as metabolizing enzyme CYP24A1 are expressed in the gonads and spermatozoa and modulate sex steroid synthesis, similarly to semen quality. That is why vitamin D supplementation is successfully used in assisted reproduction (Boisen et al., 2017). Major studies in this field are needed.
Theoretically, bone marrow adipokines also have a systemic endocrine effect, which are known to negatively influence the cardiometabolic status (Sulston and Cawthon, 2016). However, the findings are mostly based on experimental results.

**Concluding remarks**

The skeleton shows unconventional meaning in the physiology and pathophysiology of the human organism, not only as target tissue for a number of systemic hormones, but also as an endocrine tissue targeting a number of extraskeletal systems. Osteocytes, which create up to 95% of all bone cells, play a fundamental role in these processes. Osteocytes function as mechano-sensors, which, via sclerostin, modulate bone remodelling. Besides sclerostin, osteocytes express phosphatoninins regulating above all the phosphate metabolism. The osteocytes are effectively modulated by vitamin D. VDR deficient animals have been shown to increase osteocyte apoptosis and have impaired cannalicular connectivity (Rolvien al., 2017).

Further endocrine cells of the skeleton involved in bone remodelling are osteoblasts, which express osteocalcin. Besides phosphate homeostasis, osteocalcin modulates the energy metabolism and male reproduction (Bonewald, 2011). Thus, this moecule shows some promise in the treatment of diabetes, insulin resistance and obesity (Ferron and Lacombe, 2014). Moreover, a correlation study in healthy older adults showed that plasma osteocalcin levels were positively associated with global cognitive performance in healthy women (Bradburn et al., 2016). Interestingly, a recent, relatively extensive study showed an associoation between high blood osteocalcin levels and low serum haemoglobin in elderly men (Lewerin et al., 2016). New knowledge of the interactions between bone and extraskeletal systems may signify a new approach, not only in the treatment of osteoporosis.
Conflict of Interest

There is no conflict of interest

Acknowledgment: This work was supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00023761 (Institute of Endocrinology, Prague, Czech Republic).
References


DUMIC-CULE I, DRACA N, LUETIC AT, JEZEK D, ROGIC D, GRGUREVIC L, VOKICEVIC S. TSH prevents bone resorption and with calcitriol synergistically stimulates


KALEM MN, KALEM Z, AKGUN N, BAKIRARAR B. The relationship between postmenopausal women’ s sclerostin levels and their bone density, age, body mass index,


MCCLUNG MR. Clinical utility of anti-sclerostin antibodies. Bone 96: 3-7 (Epub Jan 20), 2017.


